The University of Southampton
University of Southampton Institutional Repository

Long-term effectiveness of adjuvant Goserelin in premenopausal women with early breast cancer

Hackshaw, Allan, Baum, Michael, Fornander, Tommy, Nordenskjold, Bo, Nicolucci, Antonio, Monson, Kathryn, Forsyth, Sharon, Reczko, Krystyna, Johansson, Ulla, Fohlin, Helena, Valentini, Miriam and Sainsbury, Richard (2009) Long-term effectiveness of adjuvant Goserelin in premenopausal women with early breast cancer Journal of the National Cancer Institute, 101, (5), pp. 341-349. (doi:10.1093/jnci/djn498).

Record type: Article


BACKGROUND: Systematic reviews have found that luteinizing hormone-releasing hormone (LHRH) agonists are effective in treating premenopausal women with early breast cancer.
METHODS: We conducted long-term follow-up (median 12 years) of 2706 women in the Zoladex In Premenopausal Patients (ZIPP), which evaluated the LHRH agonist goserelin (3.6 mg injection every 4 weeks) and tamoxifen (20 or 40 mg daily), given for 2 years. Women were randomly assigned to receive each therapy alone, both, or neither, after primary therapy (surgery with or without radiotherapy/chemotherapy). Hazard ratios and absolute risk differences were used to assess the effect of goserelin treatment on event-free survival (breast cancer recurrence, new tumor or death), overall survival, risk of recurrence of breast cancer, and risk of dying from breast cancer, in the presence or absence of tamoxifen.
RESULTS: Fifteen years after the initiation of treatment, for every 100 women not given tamoxifen, there were 13.9 (95% confidence interval [CI] = 17.5 to 19.4) fewer events among those who were treated with goserelin compared with those who were not treated with goserelin. However, among women who did take tamoxifen, there were 2.8 fewer events (95% CI = 7.7 fewer to 2.0 more) per 100 women treated with goserelin compared with those not treated with goserelin. The risk of dying from breast cancer was also reduced at 15 years: For every 100 women given goserelin, the number of breast cancer deaths was lower by 2.6 (95% CI = 6.6 fewer to 2.1 more) and 8.5 (95% CI = 2.2 to 13.7) in those who did and did not take tamoxifen, respectively, although in the former group the difference was not statistically significant.
CONCLUSIONS: Two years of goserelin treatment was as effective as 2 years of tamoxifen treatment 15 years after starting therapy. In women who did not take tamoxifen, there was a large benefit of goserelin treatment on survival and recurrence, and in women who did take tamoxifen, there was a marginal potential benefit on these outcomes when goserelin was added.

Full text not available from this repository.

More information

Published date: 24 February 2009


Local EPrints ID: 79502
ISSN: 0027-8874
PURE UUID: 035e684e-64fa-4103-9f17-0e6d342813a9

Catalogue record

Date deposited: 16 Mar 2010
Last modified: 18 Jul 2017 23:17

Export record



Author: Allan Hackshaw
Author: Michael Baum
Author: Tommy Fornander
Author: Bo Nordenskjold
Author: Antonio Nicolucci
Author: Kathryn Monson
Author: Sharon Forsyth
Author: Krystyna Reczko
Author: Ulla Johansson
Author: Helena Fohlin
Author: Miriam Valentini
Author: Richard Sainsbury

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.